Loading...
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis
Sorafenib confers a survival benefit for patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh (CP) A liver cirrhosis. At present, limited data exists with regard to the safety and efficacy of sorafenib in treating CP-B HCC patients. The present study describes the use of sorafenib in...
Saved in:
Published in: | Oncol Lett |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Artigo |
Language: | Inglês |
Published: |
D.A. Spandidos
2015
|
Subjects: | |
Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4356395/ https://ncbi.nlm.nih.gov/pubmed/25789012 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2015.2960 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|